Aligos Therapeutics, Inc. ALGS
2.57 USD -1.38 (-34.94%)
At closeNov 10, 2026, 7:58 PM EST
2.87 +0.30 +11.67%
After hours · Nov 10, 7:58 PM ET
2.56 Day range 3.95
2.56 52-week range 13.69
- YTD
- -72.42%
- 1 year
- -62.70%
News
benzinga.com Aligos Therapeutics Q3 EPS $(2.09) Beats $(2.28) Estimate, Sales $2.830M Miss $5.543M Estimate Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.09) per share which beat the analyst consensus estimate of $(2.28) by 8.33 percent. This is a 31.25 percent increase over losses of…
globenewswire.com Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through…
globenewswire.com Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026 SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through…
gurufocus.com Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:
benzinga.com Aligos Therapeutics Announces Acceptance Of Five Abstracts At American Association For Study Of Liver Disease's The Liver Meeting Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today…
globenewswire.com Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through…
gurufocus.com Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. Cue Biopharma (NASDAQ:CUE) stock…
benzinga.com Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
benzinga.com Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
defenseworld.net Aligos Therapeutics (NASDAQ:ALGS) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Analysis Aligos Therapeutics (NASDAQ: ALGS - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will…
defenseworld.net Aligos Therapeutics, Inc. $ALGS Shares Bought by Bank of America Corp DE Bank of America Corp DE grew its holdings in shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS) by 1,652.8% in the undefined quarter, according to the company in its most recent 13F filing with the…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)…
globenewswire.com Aligos Therapeutics to Present at the Cantor Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through…
benzinga.com Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV…
globenewswire.com Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release,…
benzinga.com Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of…
globenewswire.com Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through…
benzinga.com Aligos Therapeutics Completes Enrollment Of HBeAg+ Patients In Its Phase 2 B-SUPREME Trial Of Pevifoscorvir Sodium To Treat Chronic Hepatitis B Virus Infection Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases,…
globenewswire.com Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics…
benzinga.com Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock Aligos Therapeutics stock rose in after-hours trading after a $25 million licensing payment and China Breakthrough Therapy designation.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The…
- benzinga.com Aligos Therapeutics Receives Upfront Payment Of $25M From Exclusive License Deal Of Pevifoscorvir Sodium In Greater China With Xiamen Amoytop; Pevifoscorvir Granted Breakthrough Therapy Designation Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced…
globenewswire.com Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage…
gurufocus.com Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
gurufocus.com Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgiser
gurufocus.com Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result- benzinga.com Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45 Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.
globenewswire.com Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir Data on the preclinical characteristics of the Aligos/Amoytop ASO…
benzinga.com Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.
globenewswire.com Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through…
benzinga.com Why Akamai Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket Akamai Technologies Inc (NASDAQ: AKAM) rose in pre-market trading after reporting strong Q1 results and raising FY26 sales guidance.- benzinga.com Aligos Therapeutics Q1 EPS $(2.21) Beats $(2.28) Estimate, Sales $2.830M Beat $500.000K Estimate Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.21) per share which beat the analyst consensus estimate of $(2.28) by 3.07 percent. This is a 4.74 percent decrease over losses of…
globenewswire.com Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through…
globenewswire.com Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through…
benzinga.com 10 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Market-Moving News for April 16th MYSE: 280% | Myseum shares are trading higher. The company announced a rebrand to Myseum.AI. ALGS: 48% | Aligos Therapeutics shares are trading higher after the company announced that it has entered…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com Earnings Scheduled For March 5, 2026 - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Earnings Scheduled For May 6, 2025 
benzinga.com Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday? Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir…- benzinga.com Earnings Scheduled For March 10, 2025